Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00781742 · ClinicalTrials.gov registry record · Phase 2
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase 2 study of Major Depressive Disorder, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 152
- Enrollment target
- 20
- Study locations
NCT00781742: Completed Phase 2 study of Major Depressive Disorder, sponsored by AstraZeneca.
NCT00781742 is a Phase 2 study of Major Depressive Disorder that has completed, run by AstraZeneca. The registered enrollment target is 152 participants, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (60% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00781742, a Phase 2 study of Major Depressive Disorder, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 152 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this research study is to determine whether AZD6765 has an effect on the patient's depression when taken together with current depression medication. In addition, information will be gathered on how well AZD6765 is tolerated, investigate the levels of AZD6765 and the levels of the current depression medication in the blood. In addition, the research staff will determine if AZD6765 has any mood or calming effects (how you feel).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AZD6765
Study Locations (20)
California
- Research Site - Los Angeles
- Research Site - Orange
- Research Site - San Diego
- Research Site - Santa Ana
Florida
- Research Site - Boca Raton
- Research Site - Gainsville
- Research Site - Hollywood
- Research Site - Jacksonville
Connecticut
- Research Site - Hartford
- Research Site - New Haven
Georgia
- Research Site - Atlanta
- Research Site - Roswell
Illinois
- Research Site - Hoffman Estates
- Research Site - Joliet
Louisiana
- Research Site - Lake Charles
- Research Site - Shreveport
Arkansas
- Research Site - Little Rock
Kansas
- Research Site - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2008-10 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
What the finished NCT00781742 record still lists
NCT00781742 is an interventional study that assigns participants to a tested intervention. The registered 152 participants enrollment target is mid-sized for trials with a published cap, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (60% lower).
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00781742 names 20 study sites across 10 states, led by California, Florida, Connecticut.
Frequently Asked Questions
What is clinical trial NCT00781742 about?
NCT00781742 is a clinical study titled "AZD6765 Severe Major Depressive Disorder (MDD) IV". The purpose of this research study is to determine whether AZD6765 has an effect on the patient's depression when taken together with current depression medication. In addition, information will be gathered on how well AZD6765 is tolerated, investigate the levels of AZD6765 and the levels of the cur...
What is the current status of trial NCT00781742?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 152 participants. The study started on 2008-10. Estimated completion is 2010-03.
What conditions does trial NCT00781742 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT00781742?
The interventions under investigation include: Placebo (DRUG), AZD6765 (DRUG).
Who is sponsoring clinical trial NCT00781742?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00781742 being conducted?
This trial has 20 study locations across Arkansas, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00781742's enrollment target sits among peer trials
152 96th of 282 higher than 187 of 282 other Major Depressive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
RECRUITING · Phase 2
-
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
RECRUITING · Phase 2
-
Study of ALTO-300 in MDD
RECRUITING · Phase 2
-
Regulation of Affect and Physiology in Depression
RECRUITING · Phase 2
-
Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)
RECRUITING · Phase 2
-
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03328078 · 152 participants · Phase 1
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- NCT04458532 · 152 participants · NA
Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer
- NCT04858334 · 152 participants · Phase 2
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- NCT04993859 · 152 participants
Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia